The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Sorry try this lin
https://youtu.be/vwg5tW00E6A
Modelling the effect of Radiotherapy on tumour growth inhibition: the head and neck tumour case head and neck tumour case
https://www.physiomics.co.uk/wp-content/uploads/2019/04/PYCAACR2019_Radiation_680_final.pdf
A Precision Dosing Application For Advanced Prostate Cancer
Chemotherapy
https://www.physiomics.co.uk/wp-content/uploads/2019/04/Abstract677-1.pdf
Pyc have now posted a tweet at their booth.
https://twitter.com/physiomics?lang=en
Good turn out at conference, plenty of tweets posted, not by Physiomics though.
https://twitter.com/hashtag/aacr2019?lang=en
Majority of the team attending/presenting today, hope this the make not the break with the tool for prostrate cancer regime they've developed.
Noticed on new site a case study of CCS1477 ( a first-in-class small molecule to treat prostate and other cancers) by Cellcentrics of which Clinical protocol approved by regulatory agency.
https://www.physiomics.co.uk/wp-content/uploads/2019/03/CC-case-study.pdf
Cellcentrics also based at Magdalen Centre( same as Physiomics).
https://www.cellcentric.com/
For the presentation of:-
677 / 10 - A precision dosing application for prostate cancer chemotherapy.
They’re there to get some serious backer for this project, or it’s one big jolly as just about all staff attending!
Presenter/Authors,
Claire Villettte, Hitesh Mistry, Fernando G. Ortega, David Orrell, Frances A. Brightman, Jim Millen, Christophe Chassagnole. Physiomics plc, Oxford, United Kingdom.
680 / 13 - Predicting the effect of radiotherapy on tumor growth inhibition and time to progression in head and neck cancer
https://www.abstractsonline.com/pp8/#!/6812/presentation/1723
https://www.abstractsonline.com/pp8/#!/6812/presentation/1720
Pyc doing Abstract on 31st, looks like all presenting, hope they are successful with this.
We have developed a precision dosing app for Docetaxel in prostate cancer which requires a single weekly classical blood test in the first chemotherapy cycle. This app has the potential to significantly improve patient outcome at low cost without disrupting current clinical practice.
For a while there has been a constant flux of sells, me thinks those days are over now, without these should see so picking up also should be news out before aacr meeting end of month.
As mentioned in results yesterday, PYC attending AACR 2019 in Atlanta March 29 to April 3rd.
Had a look, unable to find any abstracts or presentations mentioned for PYC, did find they have an exhibition booth though.
https://aacr19.mapyourshow.com/7_0/exhview/index.cfm?selectedBooth=1851&CFID=43331354&CFTOKEN=49bb3877f907d6a8-CD01E8BF-9A5E-9271-26F5A2A8C053D9AE
Not putting a damper on expectations, it could well be that we may not hear anything. In the past at different periods of time PYC have announced collaborations with 3 different companies, with each one we never heard what had happened as nothing materialised with the collaborations. I know we are in a different situation here with Merck Kgaa. Also with Jim on board he may well like to keep us up to date, we'll just have to see what happens in next week or so. Have been with PYC for years and years so would like some positive news. GLA.
Jim at C2 booth. He doesn't look very inviting to potential customers. https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://twitter.com/physiomics%3Flang%3Den&ved=2ahUKEwjpxZiQ0tTeAhVK3KQKHfjAC3oQFjAAegQIBhAB&usg=AOvVaw2gdiLq4CWBOPaWmywRj7Te&cshid=1542224789134
Definite RNS on 20th. From AGM "All resolutions have been passed".
Physiomics booth is at C2, with competitors next to it booth C3 ProQinase GmbH ( a German cancer drug discovery platform).
https://www.ecco-org.eu/Events/ENA2018/Exhibition-and-Sponsorship/Floorplan#floorplanoverviewform
Has been updated to include latest recruit Dr Claire Villette profile. https://www.physiomics-plc.com/about/team/ Noticed number of buys this morning have sold up now.
https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-pyc/physiomics-shares/news/does-physiomics-plcs-lonpyc-ceo-pay-reflect-performance/amp/&ved=2ahUKEwiwrvbFoq7eAhUIIMAKHY7bCc4QFjADegQICRAB&usg=AOvVaw0d4DS3_tHpDGkSdYXrLuzH&cf=1 In 2016 Jim Millen was appointed CEO of Physiomics Plc (LON:PYC). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid